The Union Budget 2026-27 has allocated ₹10,000 crore to the new Biopharma SHAKTI scheme, which will run over the next five years. A fresh Press Information Bureau backgrounder dated 21 March 2026 confirms the Department of Pharmaceuticals is aggressively shifting focus from basic generic medicines to high-value biological drugs.
Biopharma SHAKTI to Disburse ₹10,000 Crore Over 5 Years
The government will use these funds to build an entirely new ecosystem for domestic biologic and biosimilar production. The plan heavily focuses on institutional capability. The department will upgrade seven existing National Institutes of Pharmaceutical Education and Research (NIPERs) and establish three new ones.
Furthermore, a massive chunk of this budget will fund a network of over 1,000 accredited clinical trial sites across India. If your desk processes industry grants or infrastructure subsidies, prepare for heavy file movement once the operational guidelines drop.
What Is the Biopharma SHAKTI Scheme in Simple Words?
Standard medicines use basic chemical synthesis. Biological drugs, or biopharmaceuticals, are derived from living cells, blood components, and tissues. They are incredibly complex to manufacture and regulate. Biopharma SHAKTI provides government funding to help domestic factories upgrade their technology to handle these living sources. It ensures India does not fall behind the West in advanced therapies.
What Is an Active Pharmaceutical Ingredient (API)?
Every medicine tablet contains a core chemical that cures the disease and a harmless filler material that gives the tablet its shape. That core chemical is the Active Pharmaceutical Ingredient (API). If you swallow a paracetamol tablet, the paracetamol itself is the API. India currently houses about 500 API manufacturers, controlling an 8% share of the global API market.
What Are Key Starting Materials (KSM) and Drug Intermediates?
You cannot manufacture an API out of thin air. You need base chemicals. A Key Starting Material (KSM) is the raw chemical foundation used to build an API. A Drug Intermediate is a chemical created halfway through the manufacturing process. It is no longer a raw KSM, but it is not yet a finished API. Both are critical for supply chain independence.
Pharmaceutical Exports Hit $30.5 Billion Mark in FY25
India shipped $30.5 billion worth of medicines abroad in 2024-25. This is a massive jump from just $1.9 billion back in 2000-01. Half of these exports go to highly regulated markets like the United States and Europe. The new India-EU and India-UK Free Trade Agreements will drop import duties to zero on many surgical and diagnostic medical devices.
Historical Comparison of Global Vaccine Supply Market Share
Twenty years ago, India struggled to meet its own domestic vaccine demands. Today, the situation has completely reversed. Indian manufacturers now supply 60% of all vaccines procured by UNICEF. For specific diseases like measles, Indian factories meet 90% of the World Health Organization’s total global demand. We also command a 40% to 70% global market share in DPT and BCG vaccines.
How to Calculate the Real Impact of Foreign Direct Investment
Foreign Direct Investment (FDI) into the drugs and pharmaceuticals sector hit ₹13,193 crore between April and September 2025 alone. If we annualize this run rate, the sector is absorbing over ₹26,000 crore for the full financial year. This capital inflow directly funds the establishment of USFDA-approved plants. India currently holds the highest number of these approved plants outside the United States.
PLI Schemes Generate ₹3,16,797 Crore in Total Pharma Sales
The government runs three separate Production Linked Incentive (PLI) schemes to reduce import dependence. The scheme for finished pharmaceuticals has vastly outperformed its original investment targets.
This table compares the financial performance of the three active PLI schemes based on September 2025 data.
| PLI Scheme Name | Target Investment | Actual Investment Achieved | Total Sales Generated |
|---|---|---|---|
| Pharmaceuticals | ₹ 17,275 Crore | ₹ 40,890 Crore | ₹ 3,16,797 Crore |
| Bulk Drugs (APIs/KSMs) | ₹ 4,330 Crore | ₹ 4,763 Crore | ₹ 2,313 Crore |
| Medical Devices | Not Specified | ₹ 1,093 Crore | ₹ 12,344 Crore |
How to Apply for Pharma MedTech Research Grants
The Scheme for Promotion of Research and Innovation in Pharma MedTech (PRIP) has a specific Component B for private entities. If you run a registered MSME or a health start-up, you can claim direct financial assistance for priority research areas. You must submit your project proposals through the Department of Pharmaceuticals online portal. A technical committee evaluates these proposals based purely on import substitution potential.
How to Apply for Factory Allotment in Medical Device Parks
The government is building three dedicated Medical Device Parks in Greater Noida, Ujjain, and Kanchipuram. To set up a factory, you cannot apply to the Central Ministry. You must submit your land allotment application directly to the respective State Industrial Development Corporation. As of December 2025, state authorities have already allotted 306 acres of land to 199 manufacturers.
How to Calculate Citizen Savings Under Jan Aushadhi Scheme
The Pradhan Mantri Bhartiya Janaushadhi Pariyojana (PMBJP) operates over 18,646 centers. A standard private market medicine costing ₹100 is typically sold for ₹20 at these centers. In 2024-25, these centers recorded total sales of ₹2,022 crore. By applying the standard 80% price difference formula, the government calculates this saved citizens exactly ₹8,000 crore in out-of-pocket expenses.
Who Is NOT Eligible for Bulk Drug Park Infrastructure Funds?
Private pharmaceutical companies cannot directly claim the ₹3,000 crore budget allocated for Bulk Drug Parks. This massive grant is strictly reserved for State implementing agencies. Currently, only Andhra Pradesh, Gujarat, and Himachal Pradesh qualify for the ₹1,000 crore individual state grants. Private companies only benefit indirectly by renting space in these state-built facilities.
What to Watch Next After This Order
The Department of Pharmaceuticals will soon issue the exact operational guidelines and forms for the Biopharma SHAKTI scheme. Watch for the official notification detailing the application process for the 1,000 clinical trial site accreditations. MSMEs should monitor the tender portal for upcoming facility upgrade subsidies related to biosimilar manufacturing.
Tip: If you are auditing subsidy claims under the Bulk Drugs PLI scheme, strictly verify the definition of Key Starting Materials (KSMs). Many companies incorrectly classify basic raw chemicals as KSMs to inflate their domestic value addition percentages and claim higher government incentives.